Epsilogen Ltd Email Format

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Epsilogen Ltd is a London-based biotechnology company focused on developing immunoglobulin E antibodies for cancer therapy. IgE antibodies are explored for potential advantages in solid tumors, including increased potency, better tumor access, and a longer tissue residence time. Its lead program targets the folate receptor alpha (FR alpha) with an anti-FR alpha IgE antibody currently in a phase I trial for ovarian cancer, noted as the first IgE therapeutic to reach the clinic.

Operating in biotechnology research, the firm maintains a relatively small workforce. In 2025, Epsilogen completed the acquisition of TigaTx, Inc., strengthening its portfolio with engineered IgA antibodies to pursue a pan-isotype approach to cancer therapy. The same year saw leadership updates with the appointment of Cristina Oliva as Chief Medical Officer, reflecting continued clinical oversight and governance.

Get verified Epsilogen Ltd emails free

Company overview Employee directory